Citigroup’s Rain Oncology Inc. Common Stock RAIN Stock Holding History

Citigroup’s Portfolio RAIN Stock Details RAIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,584	Closed	-$3.1K	–	5945
2023 Q4	$3.1K	Buy	2,584 +2,339	+955%	+$2.52K	﹤0.01%	5380
2023 Q3	$211	Sell	245 -4,866	-95%	-$5.33K	﹤0.01%	5316
2023 Q2	$6.13K	Sell	5,111 -35,631	-87%	-$178K	﹤0.01%	5155
2023 Q1	$356K	Buy	40,742 +13,784	+51%	+$127K	﹤0.01%	3367
2022 Q4	$216K	Buy	26,958 +26,734	+11,935%	+$168K	﹤0.01%	3679
2022 Q3	$1K	Sell	224 -215	-49%	-$1.35K	﹤0.01%	5722
2022 Q2	$2K	Sell	439 -838	-66%	-$2.88K	﹤0.01%	5946
2022 Q1	$6K	Sell	1,277 -4,295	-77%	-$34.4K	﹤0.01%	5777
2021 Q4	$72K	Buy	5,572 +4,701	+540%	+$67.2K	﹤0.01%	4904
2021 Q3	$13K	Buy	871 +211	+32%	+$3.6K	﹤0.01%	5412
2021 Q2	$10K	Buy	+660	New	+$11.6K	﹤0.01%	5682

Citigroup's RAIN Position: Q1 2024 in Review

Citigroup sold out of Rain Oncology Inc. Common Stock (RAIN) in Q1 2024, closing a stake of 2,584 shares — an estimated $3.1K sold.

Citigroup first reported a position in RAIN in Q2 2021 and held it in 11 quarters. The position peaked at $356K in Q1 2023. 0 funds tracked by Wall St. Rank hold RAIN as of Q1 2024.

Citigroup reported no remaining Rain Oncology Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citigroup sold 2,584 Rain Oncology Inc. Common Stock shares in Q1 2024, an estimated $3.1K.
Citigroup first reported a position in Rain Oncology Inc. Common Stock in Q2 2021 and held it in 11 quarters.
Citigroup's Rain Oncology Inc. Common Stock position peaked at $356K in Q1 2023.
0 funds tracked by Wall St. Rank held Rain Oncology Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.